| Literature DB >> 34403080 |
Luís Cláudio Lima de Jesus1, Thiago de Jesus Sousa1, Flávia Figueira Aburjaile1, Vasco Azevedo2, Nina Dias Coelho-Rocha1, Rodrigo Profeta1, Fernanda Alvarenga Lima Barroso1, Mariana Martins Drumond3, Pamela Mancha-Agresti4, Ênio Ferreira5, Bertram Brenig6.
Abstract
Lactobacillus delbrueckii subsp. lactis CIDCA is a new potential probiotic strain whose molecular basis attributed to the host's benefit has been reported. This study investigated the safety aspects of Lactobacillus delbrueckii subsp. lactis CIDCA 133 based on whole-genome sequence and phenotypic analysis to avoid future questions about the harmful effects of this strain consumption. Genomic analysis showed that L. delbrueckii subsp. lactis CIDCA 133 harbors virulence, harmful metabolites, and antimicrobial resistance-associated genes. However, none of these genetic elements is flanked or located within prophage regions and plasmid sequence. At a phenotypic level, it was observed L. delbrueckii subsp. lactis CIDCA 133 antimicrobial resistance to aminoglycosides streptomycin and gentamicin antibiotics, but no hemolytic and mucin degradation activity was exhibited by strain. Furthermore, no adverse effects were observed regarding mice clinical and histopathological analysis after the strain consumption (5 × 107 CFU/mL). Overall, these findings reveal the safety of Lactobacillus delbrueckii subsp. lactis CIDCA 133 for consumption and future probiotic applications.Entities:
Keywords: CRISPR-Cas system; Epithelial barrier; Genomic analysis; Lactobacillus delbrueckii; Safety assessment
Mesh：
Substances：
Year: 2021 PMID： 34403080 DOI： 10.1007/s12602-021-09826-z
Source DB: PubMed Journal: Probiotics Antimicrob Proteins ISSN： 1867-1306 Impact factor: 5.265